Autopsy report · NCT00307931

Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab

“Study was terminated early because of slow recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 1 month before it started.
• Ran for about 1 year 4 months before it stopped.
• 16 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

UCB Pharma

Sponsor type

Industry

Conditions

Crohn's Disease

Interventions

Certolizumab pegol

Participants

16

Sites

5

Countries

Greece

Trials that died the same way

• Alfuzosin Versus Placebo in Acute Urinary Retention
  “The study was early terminated due to slow and difficult recruitment” (96% match in meaning)
• THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)
  “Study terminated due to slow recruitment.” (95% match in meaning)
• Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation
  “Slow recruitment; Study was terminated for futility reasons” (93% match in meaning)
• A Study to Determine the Performance of the Press Fit Condylar (P.F.C.) Sigma RP-F Knee System
  “Study was terminated early due to prolonged recruitment period.” (93% match in meaning)
• Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
  “Study terminated early due to difficulties in subject recruitment” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.